These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 23984894

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S, Buchner D, Craver C, Gayle J.
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM.
    J Support Oncol; 2003 Apr; 1(2):89-103. PubMed ID: 15352652
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM.
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
    [Abstract] [Full Text] [Related]

  • 9. The current status of the use of palonosetron.
    Navari R.
    Expert Opin Pharmacother; 2013 Jul; 14(10):1281-4. PubMed ID: 23647207
    [Abstract] [Full Text] [Related]

  • 10. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Palonosetron: in the prevention of nausea and vomiting.
    Yang LP, Scott LJ.
    Drugs; 2009 Nov 12; 69(16):2257-78. PubMed ID: 19852528
    [Abstract] [Full Text] [Related]

  • 14. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
    Navari RM.
    Future Oncol; 2010 Jul 12; 6(7):1073-84. PubMed ID: 20624119
    [Abstract] [Full Text] [Related]

  • 15. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients.
    Aapro MS, Macciocchi A, Gridelli C.
    J Support Oncol; 2005 Jul 12; 3(5):369-74. PubMed ID: 16218261
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y, Sun W, Gu D, Yang J, Xu Z, Chen J.
    Eur J Cancer Care (Engl); 2013 Jan 12; 22(1):41-50. PubMed ID: 22519361
    [Abstract] [Full Text] [Related]

  • 18. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann C, Herrstedt J.
    Expert Rev Anticancer Ther; 2010 Feb 12; 10(2):137-48. PubMed ID: 20131990
    [Abstract] [Full Text] [Related]

  • 19. Emerging treatments in chemotherapy-induced nausea and vomiting.
    Grunberg SM, Slusher B, Rugo HS.
    Clin Adv Hematol Oncol; 2013 Feb 12; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819
    [Abstract] [Full Text] [Related]

  • 20. Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.
    Lin SJ, Hatoum HT, Buchner D, Cox D, Balu S.
    BMC Health Serv Res; 2012 Jul 23; 12():215. PubMed ID: 22823909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.